BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Verenium Corporation 

4955 Directors Place

San Diego  California  92121  U.S.A.
Phone: 800-526-5000 Fax: n/a


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Verenium Corporation (Nasdaq: VRNM) was formed in June of 2007 through the merger of Diversa Corporation, a global leader in industrial enzyme discovery and development, and Celunol Corporation, a company on the forefront of developing cellulosic ethanol.

Verenium is using its proprietary technologies and world-class expertise in pre-treatment, novel enzyme development, fermentation, engineering and project development to accelerate the development and commercialization of cellulosic ethanol from a wide array of feedstocks, including sugarcane bagasse, dedicated energy crops, agricultural waste and wood products.

By using theses integrated end-to-end capabilities, Verenium is positioned to be the first to produce cellulosic ethanol on a commercial-scale.

In addition, the Company discovers and optimizes enzymes, proteins that act as the catalysts of biochemical reactions, for the biofuels, specialty industrial processes and health & nutrition markets. Verenium currently has a portfolio of commercialized enzyme products as well as several late-stage product candidates.

For more information on Verenium, please visit www.verenium.com.

 Key Statistics


Email:
Ownership: Public

Web Site: Verenium Corporation
Employees:
Symbol: VRNM
 



Industry
Biotechnology


Collaborations

Merck & Co., Inc.  Therapeutic antibodies





 Company News
Verenium Corporation (VRNM) To Sponsor And Present At The 2013 Biotechnology Industry Organization (BIO) Pacific Rim Summit On Industrial Biotechnology And Bioenergy 12/2/2013 6:50:19 AM    More...
BASF Pays About $51.2 Million for Verenium Corporation (VRNM); Verenium Stock Rises +58.17% at Market Close (September 20, 2013) 9/20/2013 6:30:56 AM    More...
Verenium Corporation (VRNM) to Present at the Rodman & Renshaw Annual Global Investment Conference 9/4/2013 6:37:39 AM    More...
Verenium Corporation (VRNM) Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2013 8/8/2013 6:38:44 AM    More...
Verenium Corporation (VRNM) to Present at Two Upcoming Conferences 8/1/2013 7:01:43 AM    More...
Novus International and Verenium Corporation (VRNM) Introduce the Newest Addition to Novus's Enzyme Solutions Portfolio: CIBENZA® PHYTAVERSE™ 7/26/2013 9:37:24 AM    More...
Verenium Corporation (VRNM) to Announce Second Quarter 2013 Financial Results 7/25/2013 7:21:04 AM    More...
Verenium Corporation (VRNM) to Sponsor and Present at the 2013 Bio World Congress on Industrial Biotechnology 6/11/2013 6:16:26 AM    More...
Verenium Corporation (VRNM) Announces Appointment of Brian Carter as Vice President of Grain Processing 6/10/2013 10:24:32 AM    More...
Verenium Corporation (VRNM) to Present at Two Upcoming Conferences 5/23/2013 6:55:00 AM    More...
12345678910...